RecruitingNCT06630650
Neuromuscular
Lambert-Eaton Myasthenic Syndrome
Also known as LEMS, Lambert-Eaton syndrome, VGCC antibody disease
Lambert-Eaton Myasthenic Syndrome is an autoimmune disorder of the neuromuscular junction caused by antibodies against voltage-gated calcium channels (VGCC) on presynaptic motor nerve terminals, impairing acetylcholine release. Approximatel
ORPHA:43393 ↗Prevalence 1 in 100,000Onset Adulthood; paraneoplastic form typically in 6th decadeAcquired autoimmune (paraneoplastic or autoimmune)
7
studies recruiting now
as of 7 Sept 2026
36
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
17 Mar 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT06078553
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
RecruitingNot applicableNCT07478172
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RecruitingPhase 1NCT07226726
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
RecruitingNot applicableNCT07136844
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 7 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Lambert-Eaton Myasthenic Syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
About Lambert-Eaton Myasthenic Syndrome
Lambert-Eaton Myasthenic Syndrome is an autoimmune disorder of the neuromuscular junction caused by antibodies against voltage-gated calcium channels (VGCC) on presynaptic motor nerve terminals, impairing acetylcholine release. Approximately 50–60% of cases are paraneoplastic, most commonly associated with small cell lung cancer (SCLC). The hallmark electrodiagnostic feature is facilitation of the compound muscle action potential (CMAP) at high-frequency repetitive nerve stimulation.
Common clinical features
Proximal limb weakness (lower limbs predominant)Paradoxical transient strength improvement after brief exertionAutonomic dysfunction (dry mouth, constipation, erectile dysfunction)Reduced or absent deep tendon reflexes that partially return after exercisePtosis and diplopia (less prominent than in myasthenia gravis)Dysphagia and dysarthriaFatigue worsening with sustained activity
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
2 approved treatments, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Amifampridine Phosphate (Amifampridine serb)Approved: Amifampridine (Ruzurgi)
Before you apply
Things trial teams commonly ask about for Lambert-Eaton Myasthenic Syndrome. Not eligibility rules; those are set by each study.
- Anti-VGCC antibody seropositivity is a key eligibility criterion for immunotherapy trials; ensure serum antibody levels are quantified at a reference neurology laboratory before applying
- Paraneoplastic LEMS requires cancer screening (chest CT and onconeural antibody panel) before trial enrolment; active cancer may be an exclusion criterion for non-oncology trials
- Quantitative Myasthenia Gravis (QMG) score and LEMS Clinical Score (LCS) are standard endpoints; baseline scores should be documented by a neuromuscular specialist
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).